A real‐world study of alemtuzumab in a cohort of Italian patients

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab

(2021) Steffen Pfeuffer et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab: Rare serious adverse events of a high-efficacy drug

(2020) Hans-Peter Hartung et al.   Multiple Sclerosis Journal

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

(2020) Tjalf Ziemssen et al.   CNS DRUGS

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

(2020) Wendy Gilmore et al.   Journal of Neuroinflammation

Prevalence of disability improvement as a potential outcome for multiple sclerosis trials

(2020) Alessio Signori et al.   Multiple Sclerosis Journal

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis

(2020) Simona Rolla et al.   Cells

Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis

(2019) Cinzia Valeria Russo et al.   Multiple Sclerosis Journal

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

(2019) Jessica Frau et al.   JOURNAL OF NEUROLOGY

Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis

(2019) L. Scappaticcio et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

(2019) Giancarlo Comi et al.   Multiple Sclerosis Journal

Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series

(2019) Konstantinos Notas et al.   Multiple Sclerosis and Related Disorders

Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features

(2018) Nadia Pariani et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

(2018) Konstantin Huhn et al.   JOURNAL OF NEUROLOGY

Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis

(2018) Thomas Wehrum et al.   NEUROLOGY

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

(2018) Francesco Saccà et al.   Multiple Sclerosis Journal

Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab

(2018) Raphaël Bernard-Valnet et al.   Multiple Sclerosis and Related Disorders

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

(2017) Aiden Haghikia et al.   LANCET NEUROLOGY

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

(2017) Tomas Kalincik et al.   LANCET NEUROLOGY

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

(2016) MD Willis et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

(2016) MD Willis et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY